Summary
Serum phenytoin concentrations have been studied in epileptic patients and healthy subjects taking tablets of phenytoin calcium (Desitin), A, phenytoin acid (Desitin), B, and phenytoin acid (Nordmark), C. Retrospective data and prospective investigation of hospitalized patients on long-term phenytoin treatment showed that significantly higher serum concentrations of phenytoin were produced by the phenytoin acid preparations B and C than by the phenytoin calcium preparation A. In a cross over study six volunteers received 200 mg/day of preparations A, B, and C for three weeks. In this study, too, higher phenytoin serum concentrations were produced by B and C than by A, although the differences were not statistically significant. The reasons for the discrepancies between the studies in healthy and epileptic subjects are discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Matthes, A.: Epilepsie, Diagnostik und Therapie für Klinik und Praxis. Stuttgart: Georg Thieme 1975
Janz, D.: Die Epilepsien. Stuttgart: Georg Thieme 1969
Kruse, R.: Die Epilepsie des Kindesalters. Stuttgart: Georg Thieme 1969
Dreyer, R.: Die Pharmakotherapie der Epilepsien. Acta clinica Geigy12 (1970)
Dreyer, R.: Pharmakotoxikologie der antiepileptischen Arzneimittel. Hamburg: Hansesches Druck- und Verlagshaus 1972
Johansen, H.E., Wiese, C.F.: The Influence of Particle Size and other Technological Factors on the Absorption and In-Vitro-Dissolution Rate of Phenytoin from Tablets. Arch. Pharmac. Chem.127, 243–250 (1970)
Tyrer, J.H., Eadie, M.J., Sutherland, J.M., Hooper, W.D.: Outbreak of Anticonvulsant Intoxication in an Australian City. Brit. Med. J.1970/4, 271–273
Bochner, F., Hooper, W.D., Tyrer, J.H., Eadie, M.J.: Factors Involved in an Outbreak of Phenytoin Intoxication. J. neurol. Sci.16, 481–487 (1972)
Finholt, P., Henriksen, G.F., Jansholt, L., Johannessen, S., Munthe-Kaas, A.W., Paulssen, R.B.: Absorption and In-Vitro-Dissolution of Phenytoin and its Sodium Salt. Medd. Norsk. Farm. Selskap34, 136–150 (1972)
Lund, L.: Clinical Significance of Generic Inequivalence of Three Different Pharmaceutical Preparations of Phenytoin. Europ. J. clin. Pharmacol.7, 119–124 (1974)
Alván, G., Bertler, A., Eeg-Olofsson, O., Karlsson, E., Sjöqvist, F., Tomson, G.: Biological Availability: A Comparison of Three Phenytoin Preparations. Läkartidningen72, 2621–2623 (1975)
Borst, S.I., Lockwood, C.H.: Plasma Level Studies on Different Brands of Sodium Diphenylhydantoin (DPH) and Primidone. Int. J. clin. Pharmacol.12, 309–314 (1975)
Manson, J.I., Beal, S.M., Margarey, A., Pollard, A.C., O'Reilly, W.J., Sansom, L.N.: Bioavailability of Phenytoin from Various Pharmaceutical Preparations in Children. Med. J. Aust.2, 590–592 (1975)
Sansom, L.N., O'Reilly, W.J., Wiseman, C.W., Stern, L.M., Derham, J.: Plasma Phenytoin Levels Produced by Various Phenytoin Preparations. Med. J. Aust.2, 593–595 (1975)
Pentikäinen, P.J., Neuvonen, P.J., Elfving, S.M.: Bioavailability of Four Brands of Phenytoin Tablets. Europ. J. clin. Pharmacol.9, 213–218 (1975)
Stewart, M.J., Ballinger, B.R., Devlin, E.J., Miller, A.Y., Ramsay, A.C.: Bioavailability of Phenytoin. A Comparison of Two Preparations. Europ. J. clin. Pharmacol.9, 209–212 (1975)
Yamamoto, K., Nakano, M., Arita, T., Takayama, Y., Nakai, Y.: Dissolution Behaviour and Bioavailability of Phenytoin from a Ground Mixture with Microcrystalline Cellulose. J. Pharm. Sci.65, 1484–1488 (1976)
Tammisto, P., Kauko, K., Viukari, M.: Bioavailability of Phenytoin. Lancet1976, 254–255
Gugler, R., Eichelbaum, M., Fröscher, W., Penin, H.: Bioverfügbarkeit von Phenytoin unter Dauertherapie. Rundbrief der Deutschen Sektion der Internationalen Liga gegen Epilepsie58, 26–27 (1977)
Personal Communication from the Manufacturer
Rambeck, B., Meijer, J.W.A.: Simultaneous Gas-Chromatographic Analysis of some Anticonvulsants and their Metabolites in Serum. In Preparation.
Crawford, J.D., Terry, M.E., Rourke, C.M.: Nomogramm zur Bestimmung der Körperoberfläche aus Gewicht und Länge. Pediatrics5, 783 (1950)
Clauß, G., Ebner, H.: Grundlagen der Statistik. Thun und Frankfurt/M.: Verlag Harri Deutsch 1977
Hays, W.L.: Statistics. London, New York, Sydney, Toronto: Holt, Rinehart and Winston 1976
Schmidt, D., Janz, D.: Die biologische Verfügbarkeit von Phenhydan, Phenhydan retard und Zentropil. Rundbrief der Deutschen Sektion der Internationalen Liga gegen Epilepsie58, 25–26 (1977)
Arnold, K., Gerber, N.: The Rate of Decline of Diphenylhydantoin in Human Plasma. Clin. Pharmacol. Ther.11, 121–134 (1970)
Gerber, N., Wagner, J.G.: Explanation of Dose-Dependant Decline of Diphenylhydantoin Plasma Levels by Fitting to the Integrated Form of the Michaelis-Menten Equation. Res. Commun. Chem. Pathol. Pharmacol.3, 455–466 (1972)
Lund, L., Alvan, G., Berlin, A., Alexanderson, B.: Pharmacokinetics of Single and Multiple Doses of Phenytoin in Man. Europ. J. clin. Pharmacol.7, 81–86 (1974)
Richens, A.: Drug Treatment of Epilepsy, pp. 9–34. London: Henry Kimpton 1976
Eadie, M.J., Tyrer, J.H., Bochner, F., Hooper, W.D.: The Elimination of Phenytoin in Man. Clin. Exp. Pharmacol. Physiol.3, 217–224 (1976)
Wilson, J.T., Höjer, B., Rane, A.: Loading and Conventional Dose Therapy with Phenytoin in Children: Kinetic Profile of Parent Drug and Main Metabolite in Plasma. Clin. Pharmacol. Ther.20, 48–58 (1976)
Wilensky, A.J., Lowden, J.A.: Increased Phenytoin Metabolism in Rabbits after Phenytoin Pretreatment. Res. Commun. Chem. Pathol. Pharmacol.15, 365–368 (1976)
Arnold, K., Gerber, N., Levy, G.: Absorption and Dissolution Studies on Sodium Diphenylhydantoin Capsules. Canad. J. Pharm. Sci.5, 89–92 (1970)
Richens, A.: Drug Treatment of Epilepsy pp. 12 and 106, London: Henry Kimpton 1976
Anschel, J.: Neues aus den USA, Bioäquivalenz. Pharm. Ind.39, 354 (1977)
Author information
Authors and Affiliations
Additional information
Dedicated to the memory of the late Friedrich v. Bodelschwingh (1902–1977)
Rights and permissions
About this article
Cite this article
Rambeck, B., Boenigk, H.E. & Stenzel, E. Bioavailability of three phenytoin preparations in healthy subjects and in epileptics. Eur J Clin Pharmacol 12, 285–290 (1977). https://doi.org/10.1007/BF00607428
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00607428